<DOC>
	<DOCNO>NCT02407041</DOCNO>
	<brief_summary>Study GT-030 phase 2a , single-center , open-label study subject moderate severe plaque psoriasis</brief_summary>
	<brief_title>An Open-Label , Phase 2a Study Evaluate Safety Efficacy GR-MD-02 Treatment Psoriasis</brief_title>
	<detailed_description>The overall objective establish safety efficacy GR-MD-02 patient moderate severe plaque psoriasis . Primary objective : The objective evaluate number patient moderate severe plaque psoriasis 75 % improvement Psoriasis Activity Severity Index ( PASI-75 ) follow 12 week therapy GR-MD-02 Secondary objective : - To determine PASI-50 PASI-100 score patient moderate severe plaque psoriasis follow first 12 week therapy GR-MD-02 - To determine PASI-50 , PASI-75 , PASI-100 score patient moderate severe plaque psoriasis follow additional 12 week therapy ( total 24 week ) GR-MD-02 - To determine durability response therapy responder one year period follow end therapy - To determine whether change disease status patient also psoriatic arthritis - To determine incidence adverse event vital sign laboratory abnormality study treatment</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Each subject must meet follow criterion enrol study : 1 . Is capable understand write informed consent , provide sign witness write informed consent , agree comply protocol requirement . 2 . Is ages 18 75 year . 3 . Has biopsy prove psoriasis active moderate severe plaque psoriasis PASI â‰¥ 12 least 10 % involve body surface area . 4 . The patient pregnant must negative pregnancy test prior start study . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 5 . Sexually active men woman childbearing potential must agree use effective mean contraception throughout participation study 90 day discontinuation study medication . 6 . Lactating female must agree discontinue nurse start study treatment refrain nurse 90 day discontinuation study medication . 7 . Male subject must refrain sperm donation throughout study period period 90 day follow last dose study drug . Subjects meet follow criterion exclude study : 1 . Any medical illness stable therapy 2 . Use biologic medication psoriasis within 6 month 3 . Use nonbiological systemic therapy include : methotrexate , oral retinoids , phototherapy/PUVA , cyclosporine , cytotoxic immunosuppressive medication within 4 week start study 4 . Topical treatment likely impact sign symptom psoriasis , opinion Principal Investigator , within 2 week start study 5 . Prior exposure GRMD02 6 . Known positivity Human Immunodeficiency Virus ( HIV ) infection 7 . Any patient major surgery within 8 week Day 1 , significant traumatic injury , anticipation need major surgical procedure study . 8 . Has history alcohol/drug abuse . 9 . Any patient clinically significant uncontrolled cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication , Grade II great peripheral vascular disease within 12 month prior Day 1 . 10 . Any patient concurrent infection include diagnosis fever unknown origin ( FUO ) ( subject must afebrile start therapy ) . 11 . History malignant disease recurrence disease within 5 year followup except curatively treat include basal squamous cell carcinoma skin situ carcinoma cervix 12 . Participation investigational new drug ( IND ) trial 30 day randomization . 13 . Clinically significant medical psychiatric condition consider high risk participation investigational study . 14 . Has donate lose significant volume ( &gt; 450 mL ) blood plasma within 30 day study . 15 . Failure give inform consent 16 . Subjects know allergy study drug excipients . 17 . Is employee family member investigator study site personnel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>